To describe the neurologic spectrum and treatment outcomes for neurochondrin-IgG positive cases identified serologically in the Mayo Clinic Neuroimmunology Laboratory.
Autoimmune causes of movement disorders are increasingly recognized, particularly for ataxia. Identification of specific autoantibody biomarkers aids the neurologic diagnosis, expedites the search for occult cancer, and may also indicate most appropriate therapy and predict outcome. For example, Purkinje cell cytoplasmic antibody type 1 (also known as anti-Yo) is generally accompanied by subacute cerebellar ataxia, breast or gynecologic adenocarcinoma, and poor response to immunotherapy. 1, 2 In contrast, cerebellar ataxia caused by metabotropic glutamate receptor 1 (mGluR1) autoimmunity is occasionally accompanied by lymphoma, and the ataxia may respond robustly to immunotherapy. 3 Herein, we describe 8 cases identified with an IgG autoantibody specific for a neuronal cytosolic protein, neurochondrin, in the course of characterizing unclassified neural-specific autoantibodies. 4, 5 Neurochondrin autoimmunity was previously described in 3 adult patients with cerebellar degeneration and in a child with chorea. 6, 7 All but 1 of the 7 patients with clinical information available in our report had predominance of rhombencephalitis (cerebellar and brainstem localization). Myelopathy and acute psychosis (accompanying ataxia) and neuropathy (without other features) were each encountered in single patients.
Methods
Standard protocol approvals, registrations, and patient consents The Mayo Clinic Institutional Review Board approved human specimen acquisition and retrospective review of patients' histories (institutional review board #08-006647).
Study population
Between January 1, 1993 and June 7, 2018, the Mayo Clinic Neuroimmunology Laboratory tested by tissue-based indirect immunofluorescence assay (IFA), 616,025 serum and CSF specimens submitted for service testing for autoimmune encephalitic disorders or a suspected paraneoplastic neurologic disorder. IgG in 89 of those specimens (25 CSF; 64 serum) yielded a synaptic-type hippocampal staining pattern of nonuniform focal intensity. All 89 archived specimens were retested by IFA and classified in detail according to their respective staining patterns. Eight patients with an identical staining pattern are the subject of this report; clinical information was available in 7, 5 by review of Mayo Clinic records and 2 by contact with external physicians.
Laboratory methods
Indirect IFA, dual staining by confocal microscopy, Western blots, immunoprecipitation assay, and sequencing by mass spectrometry and neurochondrin-specific cell-based assays were undertaken, as previously described (appendix e-1, links. lww.com/NXI/A143). 8 
Results

Neural autoantigen characterization
Immunohistochemical distribution
An identical CNS-restricted pattern of immunoreactivity (synaptic and cytoplasmic regions) was detected in 12 specimens from 8 patients (8 serum; 4 CSF; figure 1, A-F). IgG bound robustly to several structures: hippocampus (particularly the stratum lucidum, continuous from CA2 and CA3 regions to the dentate gyrus granular cell layer), cerebellum (Purkinje neuronal cytoplasm and diffusely in molecular layer), and amygdala. Staining was less intense in the striatum, thalamus, and cerebral cortex. Myenteric nerves had faint staining, and parenchyma of kidney and gut were nonreactive (not shown). Median endpoint dilutions were 1: 30,720 in serum (range, 1:3,840-1:61,440) and 1:64 in CSF (range, 1:2-1:256).
Autoantigen identification
Application of patient sera, but not healthy control sera, to immunoblots of mouse cerebral lysates, revealed a common immunoreactive band of approximate molecular weight 75 kDa (figure e-1, links.lww.com/NXI/A142). A candidate antigen was identified by protein G magnetic bead capture from mouse cerebral lysate using sera from patients 1, 4, and 6 (figure 1G). Mass spectrometry analysis of the electrophoretically separated proteins predicted the 75 kDa protein to be neurochondrin.
Dual IFA staining on mouse brain sections demonstrated colocalization of patient IgGs with a commercial neurochondrin polyclonal IgG, figure 2, A-D. Sera from patients 1-6, but not 3 healthy control sera, bound to recombinant full-length neurochondrin protein (Abcam [product number ab161548, glutathione S-transferases-tagged at N terminus], figure 2E ). All patient specimens and 2 of 196 healthy control sera were positive by neurochondrin-specific cell-based assay; IgGs bound to neurochondrin-expressing cells, but not mock transfected cells (figure 2, F-G). Unlike the patient specimens, none of the 196 healthy control sera produced neural IgG staining by tissue-based IFA.
Summary of demographic and clinical findings
Six of 8 patients were identified retrospectively from the Mayo Clinic Neuroimmunology Laboratory archives (1997-2018) and 2 patients were identified prospectively after the study Glossary IFA = immunofluorescence assay; IVIg = IV immune globulin. was underway. Five were female. The median symptom onset age was 43 years (range, 30-69).
Neurological manifestations
Clinical information was available for 7 of 8 patients (shown in table 1). Five of 7 were evaluated neurologically at the Mayo Clinic. The median follow-up period was 18 months (range, 2-60). Six of 7 patients presented with a rapidly progressive rhombencephalitis (cerebellar/brainstem) over the course of a few weeks. The remaining patient had symptoms of small fiber neuropathy and dysautonomia (pain, paresthesia, and constipation) without CNS findings. 
Imaging
Brain MRI images from early in the disease course were available for review in all patients with cerebellar or brainstem symptoms and signs, with the exception of patient 8 ( 
Treatment and outcomes
Five of 6 patients with an ataxic or brainstem syndrome were treated with immunotherapy within 1 month of symptom onset (corticosteroids, 5; IV immune globulin [IVIg], 3; plasma exchange, 1). Despite early intervention, only 1 patient (patient 6) remained ambulatory; she had received corticosteroids. Three patients became wheelchair-bound, and 1 died from complications of neurologic progression. One patient who commenced treatment 1 year after symptom onset remained wheelchair-bound. It was the opinion of the prescribing physicians that some immune therapies (rituximab, azathioprine, IVIg) slowed the rate of disease progression (3) or mildly improved symptoms (patient 6 who received both IV and oral corticosteroids, and azathioprine, table 1).
Discussion
We report 8 patients in whom we identified neurochondrin IgG incidentally in the course of characterizing an unclassified neural-specific IgG autoantibody. Specificity was confirmed by affinity purification of the antigen, mass spectrometry, confocal microscopy and protein-specific assays (Western blot and transfected cell-based).
Neurochondrin is a leucine-rich protein expressed in brain, bone (osteoblasts and osteoclasts), and cartilage. 5,9 It enhances cell-surface localization of certain membrane-bound proteins, such as metabotropic glutamate receptors, but is itself a cytoplasmic antigen. 5 While reliable as a biomarker of neurologic autoimmunity, neurochondrin-IgG is not pathogenic, but likely a proxy for a cytotoxic T cell-mediated pathogenesis. Consistent with our clinical findings, neurochondrin is highly expressed in cerebellar Purkinje cells, the brainstem, the lateral parts of the central amygdalar nuclei, the hippocampal pyramidal cells, and also the autonomic and peripheral nervous systems. 4 Relevant to the psychosis, myelopathy, and neuropathy phenotypes, respectively, neurochondrin knockout mice have a schizophrenia-like behavioral phenotype, neurochondrin is required for the correct localization of a survival motor neuron protein, and is expressed in rat peripheral nerve. 5, 10, 11 In bone, neurochondrin inhibits osteoclast-and macrophage-induced hydroxyapatite bone resorption. 12 None of our patients was known to have had metabolic bone disease.
We confirm the principal clinical accompaniments originally described, namely, severe cerebellar ataxia and other features of rhombencephalitis, and usually without evidence of systemic cancer. Other phenotypes include chorea 7 and small fiber neuropathy (reported herein). Two of our patients with rhombencephalitis had additional neuropsychiatric findings (psychosis or myelopathy). Neuroradiological findings were diverse, though were cerebellum and brainstem predominant. The diversity of cerebellar and extracerebellar T2 abnormalities, not typical for other autoimmune ataxias, could serve as a clue to neurochondrin CNS autoimmunity.
Neurochondrin IgG is one of several reported biomarkers of autoimmune ataxias with (usually) nonparaneoplastic, idiopathic autoimmune cause. [13] [14] [15] These are listed in order of reported commonality in table 2.
The almost universal lack of neurologic improvements from immunotherapies in neurochondrin autoimmunity is consistent with other nonantibody-mediated, intracellular antigen-defined autoimmune ataxias, for some of which CD8 + cytotoxic T-cell infiltrative immunopathology has been demonstrated. 6, 16, 17 We identified 1 patient who remained ambulatory after corticosteroid therapy and did not progress after treatment with azathioprine. It is possible that future patients treated early with high-dose steroids and T celldirected therapy (cyclophosphamide) might have better outcomes. The most robust responses to immune therapies have been reported among autoimmune ataxia patients harboring antibodies reactive with cell surface antigens (table 2) . 16 For patients presenting with unexplained ataxia or brainstem symptoms and signs of subacute onset, comprehensive neural IgG screening with tissue-based immunohistochemistry permits simultaneous evaluation for a growing list of neuralspecific IgGs, including neurochondrin-IgG.
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